SCHEMBL1795508

SCHEMBL1795508

COC(=O)c1cc(Br)ccc1NC(=O)COCC(=O)NC(c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.55
GAA P10253 2/20 0.55
TSHR P16473 2/20 0.51
KMT2A Q03164 3/20 0.47
MEN1 O00255 1/20 0.47
HSD17B10 Q99714 3/20 0.46
MAPK10 P53779 1/20 0.46
KDM4E B2RXH2 5/20 0.44
HTT P42858 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 4/20 0.43
MAPK1 P28482 1/20 0.43
POLB P06746 3/20 0.42
PSMD14 O00487 1/20 0.42
MMP2 P08253 1/20 0.42
DNMT1 P26358 1/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1798978 0.87 SERPINE1 (0.53) ALDH1A1GAATSHRKMT2AMEN1
SCHEMBL1796641 0.84 ALDH1A1 (0.57) ALDH1A1GAATSHRKMT2AMEN1
SCHEMBL1796132 0.83 TSHR (0.47) ALDH1A1GAATSHRKMT2AHSD17B10
SCHEMBL16632075 0.83 ALDH1A1 (0.60) ALDH1A1GAATSHRKMT2AMEN1
SCHEMBL1799009 0.83 TSHR (0.46) ALDH1A1TSHRKMT2AHSD17B10MAPK10
SCHEMBL1795511 0.80 ALDH1A1 (0.54) ALDH1A1GAATSHRKMT2AMEN1
SCHEMBL1798806 0.80 SERPINE1 (0.67) ALDH1A1GAAMAPK1
SCHEMBL15647271 0.79 ALDH1A1 (0.72) ALDH1A1GAATSHRKMT2AMEN1
SCHEMBL1796300 0.77 ALDH1A1 (0.48) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL22660771 0.77 ALDH1A1 (0.68) ALDH1A1GAATSHRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 US disclosed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 ALDH1A1 800/4885GAA 721/4885TSHR 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.